161 related articles for article (PubMed ID: 37536990)
1. [
Shi J; Zheng DW; Ma XG; Su RY; Zhu YK; Wang SH; Chang WJ; Sun GQ; Sun DY
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):797-805. PubMed ID: 37536990
[No Abstract] [Full Text] [Related]
2. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
3. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
4.
Li F; Wan L; Xiao T; Liu H; Jiang Y; Zhao X; Wang R; Wan K
Biomed Res Int; 2018; 2018():3579832. PubMed ID: 30065936
[TBL] [Abstract][Full Text] [Related]
5. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Kurz SG; Wolff KA; Hazra S; Bethel CR; Hujer AM; Smith KM; Xu Y; Tremblay LW; Blanchard JS; Nguyen L; Bonomo RA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6085-96. PubMed ID: 24060876
[TBL] [Abstract][Full Text] [Related]
6.
Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
[TBL] [Abstract][Full Text] [Related]
7.
Economou Lundeberg E; Andersson V; Wijkander M; Groenheit R; Mansjö M; Werngren J; Cortes T; Barilar I; Niemann S; Merker M; Köser CU; Davies Forsman L
Microbiol Spectr; 2023 Sep; 11(5):e0178123. PubMed ID: 37737628
[TBL] [Abstract][Full Text] [Related]
8. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
9. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
10. Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of
Olivença F; Pires D; Silveiro C; Gama B; Holtreman F; Anes E; Catalão MJ
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0158623. PubMed ID: 38411952
[TBL] [Abstract][Full Text] [Related]
11. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
12. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.
Misawa K; Nishimura T; Kashimura S; Enoki Y; Taguchi K; Uno S; Uwamino Y; Matsumoto K; Hasegawa N
Int J Antimicrob Agents; 2022; 60(5-6):106669. PubMed ID: 36064079
[TBL] [Abstract][Full Text] [Related]
17. The
Andersson V; Fröberg G; Dahl VN; Chryssanthou E; Giske C; Schön T; Forsman LD
Int J Mycobacteriol; 2023; 12(3):211-225. PubMed ID: 37721224
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.
Horita Y; Maeda S; Kazumi Y; Doi N
Antimicrob Agents Chemother; 2014 Nov; 58(11):7010-4. PubMed ID: 25224000
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of β-Lactam Antibiotics and Genetic Mutation of Drug-Resistant Mycobacterium tuberculosis Isolates in Korea.
Park S; Jung J; Kim J; Han SB; Ryoo S
Tuberc Respir Dis (Seoul); 2022 Jul; 85(3):256-263. PubMed ID: 35586904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
